Unilever Maintains Sell Rating with Target Price of 4,440 Pence

Overview

This report is based on UBS's interpretation of Unilever's management presentation. The core view is that while the company demonstrates strong operational momentum and a clear long-term strategy (i.e., food business spin-off by mid-2027), the current stock price has already fully priced in these optimistic expectations, and near-term cost pressures remain significant. Therefore, the 'Sell' rating is maintained. The report acknowledges that even post-spin-off, the core Home & Personal Care (HPC) business remains competitive, but overall valuation is deemed too high, limiting investment appeal.

Core views

The report highlights that Unilever's management conveyed strong confidence during the presentation. First, the company reaffirmed its 2026 guidance: underlying sales growth (USG) in the lower end of the 4%-6% range, volume growth exceeding 2%, and modest improvement in underlying operating margins. However, achieving this guidance faces challenges, as the company anticipates additional commodity costs of €750-900 million in 2026, half of which stems from the Home Care division. Management remains positive, believing that price increases, cost savings, and product reformulation can absorb most of this pressure. Second, the report places significant emphasis on the upcoming strategic spin-off of the food business. Management explicitly frames this as a value-creating initiative. Post-spin-off, the standalone Home & Personal Care (HPC) business is expected to benefit from a more focused structure and reduced complexity, with projected volume growth exceeding 2%, gross margins above 48%, and operating margins surpassing 19%. Furthermore, the business's profit potential remains elevated, driven by brand equity growth, premiumization trends, and capital allocation prioritizing efficiency improvements. Finally, the report underscores the company's strengths in innovation and market expansion. For instance, 26 of its brands in the U.S. are integrated into Amazon Sponsored Products, becoming key purchase pathways. In digital health, brands such as LiquidIV and Nutrafol are expanding rapidly, with China revenues nearing €80 million. These initiatives demonstrate the company's active leveraging of digitalization and emerging consumer trends to drive growth.

Analysis framework

The firm employs a comprehensive analytical framework. First, from a fundamental perspective, it evaluates core operating metrics—including sales growth (USG), volume growth (UVG), gross margin, and operating margin—comparing them against industry averages to assess competitive advantages. Second, it incorporates macroeconomic and structural factors, focusing on the impact of commodity inflation on profitability and evaluating management's mitigation strategies. Third, it conducts scenario analysis around major events (e.g., spin-off) to forecast the financial performance of the independent entities post-separation. Finally, all conclusions are grounded in a core valuation model: Discounted Cash Flow (DCF), with a weighted average cost of capital (WACC) of 7.5% and a terminal growth rate of 1.8%.

Methodology notes

• Valuation MethodDCF Discounted Cash Flow

  The Discounted Cash Flow (DCF) model is used to estimate the company's intrinsic value, a standard approach for assessing long-term enterprise value.

  The DCF model forecasts the company's future free cash flows and discounts them to their present value using a reasonable discount rate (here, 7.5% WACC) to derive a theoretical valuation. The method hinges on realistic cash flow projections and appropriate risk assessment.

• Company Fundamentals & Financial FrameworkROIC–WACC spread

  Analyzes the spread between Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC) to measure the company's ability to create shareholder value.

  If a company's ROIC exceeds its WACC, it indicates value creation for shareholders. The report notes that the standalone HPC business's projected ROIC will significantly outperform peers, forming a key rationale for its investment appeal.

• Industry/Market Analysis FrameworkSupply and Demand Framework

  Analyzes the impact of commodity price fluctuations on upstream manufacturing costs, representing a classic supply-side analysis.

  In the consumer goods industry, raw material prices (e.g., crude oil, vegetable oils) are primary cost drivers. When commodity prices rise and cannot be fully passed on through pricing, margins are compressed. The report applies this framework to assess Unilever's cost pressures and its capacity to respond.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Unilever (ULVR.L)

  As the core subject, its spin-off plan and cost management form the central analytical logic of the report.

  Strengths

  Strong management confidence, excellent performance in core HPC business, strong innovation capability, leading digital positioning.

  Weaknesses

  Significant commodity cost pressures, currently perceived as overvalued, lacks near-term catalysts for price appreciation.

  Comparison

  Compared to peers, its core business demonstrates clear advantages in volume growth and margins.

  Risks

  Further commodity price increases, weak consumer demand, delays or failure in spin-off transaction, intensified competition

Key data

• 2026 Underlying Sales Growth Guidance4%-6%At the lower end of the guidance range
• 2026 Additional Commodity Costs€750-900mPrimarily driven by Home Care segment
• Post-Spin-off Pure-play HPC Gross Margin>48%Significantly higher than current levels
• Post-Spin-off Pure-play HPC Operating Margin>19%Above peer average; target of 22-23%
• Post-Spin-off Pure-play HPC Volume Growth>2%Above peer average of 0.3%

Impact & implications

For investors, this report implies that Unilever's long-term strategic outlook is bright, particularly after the food spin-off, when its core HPC business will be more focused and profitable. However, the current stock price has already priced in this optimism. Therefore, UBS believes that absent significant negative catalysts (e.g., uncontrolled cost escalation or sharp demand decline), near-term upside potential is limited, and downside risk from valuation re-rating remains. The 'Sell' recommendation implies an unfavorable risk-reward profile at current levels.

Risks

• Commodity prices continue to rise beyond expectations
• Regulatory delays or failure in the food business spin-off
• Declining consumer spending leading to weak demand
• Intensified competition in core business segments

What to watch

• Q2 2026 earnings report to validate cost control and volume growth
• Latest developments on the spin-off transaction, especially antitrust review status
• Performance in U.S. and India markets, which together account for 40-45% of total sales